Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bevacizumab + Carboplatin + Paclitaxel + Ubamatamab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bevacizumab | Avastin | VEGF Antibody 17 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
| Ubamatamab | REGN-4018|REGN 4018|REGN4018 | CD3 Antibody 126 MUC16 Targeted Therapy 12 | Ubamatamab (REGN4018) is a bispecific antibody that binds MUC16 (CA125) on tumor cells and CD3 on T-cells to stimulate T-cell killing of MUC16-expressing tumor cells (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1777, PMID: 31217340). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07637851 | Phase Ib/II | Bevacizumab + Carboplatin + Paclitaxel + Ubamatamab Bevacizumab + Ubamatamab Bevacizumab + Olaparib | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (RegeNovar) | Not yet recruiting | FRA | 0 |